Abstract 4131775: Effectiveness of Lipid-lowering therapy with Bempedoic Acid plus Ezetimibe in a Real-world Cohort
Abstract
Introduction: Bempedoic acid and the combination with ezetimibe (BA+EZE) have demonstrated low-density lipoprotein cholesterol (LDL-C) lowering in clinical trials of adults with primary hyperlipidemia at high risk for or with cardiovascular disease. The impact of BA+EZE on LDL-C outcomes in a real-world cohort has not been studied. Aim: To evaluate the effectiveness of BA+EZE on LDL-C reduction and goal achievement using real-world data. Methods: This was a retrospective cohort study using deidentified electronic health records and linked claims data. Adult patients were included if they had a pharmacy claim for BA+EZE from March 1, 2020 to March 15, 2024 (date of first pharmacy claim = index date ), had ≥1 baseline LDL-C lab result on or within 6 months prior to the index date, and ≥2 LDL-C lab results post-index, including 1 lab result 12 months post-index (±60 days). Patients with documented use of ezetimibe on or within 6 weeks prior to index were excluded. For all patients with available valid lab results, LDL-C was determined at baseline (the value closest to but not after the index date), 3 months (±30 days), 6 months (±60 days) and 12 months (±60 days). Results: A total of 615 BA+EZE patients were identified (mean age 62±11 years, 52% women). At baseline, 64% had evidence of statin use in the prior 12 months and the mean LDL-C was 131±52 mg/dl. Figure 1 shows the change in the proportion of patients achieving LDL-C control at index, 3-, 6-, and 12-months post-index. T…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In that analysis, patients on bempedoic acid plus ezetimibe achieved a 28.0% reduction at 3 months, with reductions of 22% sustained at 12 months (p<0.001).
“Patients on bempedoic acid plus ezetimibe achieved a 28.0% reduction at 3 months, with reductions of 22% sustained at 12 months versus baseline (baseline LDL-C = 131 mg/dL) (p < 0.001) [31].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [31]
In a large retrospective analysis of patients with a prescription claim for bempedoic acid, bempedoic acid monotherapy reduced LDL-C by 18.0% at 3 months, with reductions sustained at 12 months (p<0.0001).
“In a large retrospective analysis of patients with a prescription claim for bempedoic acid, regardless of cardiovascular risk status, bempedoic acid monotherapy reduced LDL-C by 18.0% at 3 months (baseline LDL-C = 137 mg/dL), with reductions sustained at 12 months versus baseline (p < 0.0001) [31].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [31]
In the same large retrospective analysis, 67.0% treated with bempedoic acid plus ezetimibe achieved an LDL-C target of <100 mg/dL (baseline LDL-C = 131 mg/dL).
“In a large retrospective analysis of patients with a prescription claim for bempedoic acid, regardless of cardiovascular risk status, 42.0% treated with bempedoic acid monotherapy (baseline LDL-C = 137 mg/dL) and 67.0% with bempedoic acid plus ezetimibe (baseline LDL-C = 131 mg/dL) achieved an LDL-C target of <100 mg/dL [31].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [31]
In a large retrospective analysis of patients with a prescription claim for bempedoic acid, regardless of cardiovascular risk status, 42.0% treated with bempedoic acid monotherapy achieved an LDL-C target of <100 mg/dL (baseline LDL-C = 137 mg/dL).
“In a large retrospective analysis of patients with a prescription claim for bempedoic acid, regardless of cardiovascular risk status, 42.0% treated with bempedoic acid monotherapy (baseline LDL-C = 137 mg/dL) and 67.0% with bempedoic acid plus ezetimibe (baseline LDL-C = 131 mg/dL) achieved an LDL-C target of <100 mg/dL [31].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [31]
In all-comer populations with mixed statin-intolerance and varied background LLTs, LDL-C reductions with bempedoic acid ranged from 18% to 42%.
“In all-comer populations with mixed statin-intolerance and varied background LLTs, LDL-C reductions also ranged from 18% to 42% [23,26,28,30,31,33,43].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [31]
- Authors
- Nelson, J., Bloedon, L., Lewandowski, D., Bonafede, M., & Sarnes, E.
- Affiliations
- Veradigm, Chicago, Illinois, United States
- Esperion Therapeutics (United States) (US)
- Venue
- Circulation
- Published
- 2024-11-12
- Volume
- 150
- Issue
- Suppl_1
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4404323599
- Cited by
- 0
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- bempedoic acid, ezetimibe, lipid-lowering therapy, LDL cholesterol lowering, LDL-C goal attainment, primary hyperlipidemia, real-world effectiveness, statin use, cardiovascular disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
